Research programme: cell therapies - Green Cross Cell Corporation

Drug Profile

Research programme: cell therapies - Green Cross Cell Corporation

Alternative Names: Autoimmune disease therapy - Green Cross Cell; Autoimmune disease therapy - Innocell; Dendritic cell therapy - Green Cross Cell; Dendritic cell therapy - Innocell; Regulatory T cell therapy - Green Cross Cell; Regulatory T cell therapy - Innocell; Stem cell therapy - Green Cross Cell; Stem cell therapy - Innocell

Latest Information Update: 31 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innocell Corporation
  • Developer Green Cross Cell
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Dendritic cell stimulants; Regulatory T-lymphocyte stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 31 May 2016 Preclinical development is ongoing in South Korea
  • 09 Sep 2013 Preclinical development is ongoing in South Korea
  • 22 Mar 2013 Innocell Corporation is now called Green Cross Cell Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top